NASDAQ:PTI

Proteostasis Therapeutics Stock Forecast, Price & News

$21.43

-0.57 (-2.59 %)

(As of 01/15/2021)

Add

Compare

Today's Range

$21.07

Now: $21.43▼

$22.22

50-Day Range

$1.00

MA: $10.08▼

$22.42

52-Week Range

$0.87

Now: $21.43▼

$2.72

Volume40,237 shs

Average Volume1.04 million shs

Market Capitalization$1.12 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.16

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

MarketRank^™

Overall MarketRank^™

0.85 out of 5 stars

1.5 Analyst's Opinion

Consensus Rating
Proteostasis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.67, Proteostasis Therapeutics has a forecasted downside of 78.2% from its current price of $21.43.
Amount of Analyst Coverage
Proteostasis Therapeutics has received no research coverage in the past 90 days.

2.1 Community Rank

Outperform Votes
Proteostasis Therapeutics has received 317 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Proteostasis Therapeutics has received 441 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Proteostasis Therapeutics has received 58.18% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote “Outperform” if you believe PTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Proteostasis Therapeutics does not currently pay a dividend.
Dividend Growth
Proteostasis Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Proteostasis Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Proteostasis Therapeutics is held by insiders.
Percentage Held by Institutions
Only 16.64% of the stock of Proteostasis Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Proteostasis Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Proteostasis Therapeutics is -25.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Proteostasis Therapeutics is -25.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Proteostasis Therapeutics has a P/B Ratio of 17.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PTI

Previous Symbol

CUSIPN/A

CIK1445283

Webwww.proteostasis.com

Phone617-225-0096

Employees44

Debt

Debt-to-Equity RatioN/A

Current Ratio6.69

Quick Ratio6.69

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5 million

Price / Sales223.66

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.22 per share

Price / Book17.57

Profitability

EPS (Most Recent Fiscal Year)($1.16)

Net Income$-59,130,000.00

Net MarginsN/A

Return on Equity-75.39%

Return on Assets-55.04%

Miscellaneous

Outstanding Shares52,185,000

Market Cap$1.12 billion

Next Earnings Date3/9/2021 (Estimated)

OptionableOptionable

$21.43

-0.57 (-2.59 %)

(As of 01/15/2021)

30 days | 90 days | 365 days | Advanced Chart

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

How has Proteostasis Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTI shares have increased by 1,747.4% and is now trading at $21.43.
View which stocks have been most impacted by COVID-19.

Is Proteostasis Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Proteostasis Therapeutics stock.
View analyst ratings for Proteostasis Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Proteostasis Therapeutics?

Wall Street analysts have given Proteostasis Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Proteostasis Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Proteostasis Therapeutics.

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) posted its earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01.
View Proteostasis Therapeutics' earnings history.

What price target have analysts set for PTI?

4 Wall Street analysts have issued 12 month price targets for Proteostasis Therapeutics' shares. Their forecasts range from $3.00 to $7.00. On average, they expect Proteostasis Therapeutics' share price to reach $4.67 in the next year. This suggests that the stock has a possible downside of 78.2%.
View analysts' price targets for Proteostasis Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Proteostasis Therapeutics' key competitors?

Some companies that are related to Proteostasis Therapeutics include Hutchison China MediTech (HCM), Arvinas (ARVN), GW Pharmaceuticals (GWPH), ChemoCentryx (CCXI), Hypera (HYPMY), Legend Biotech (LEGN), Insmed (INSM), FibroGen (FGEN), Apellis Pharmaceuticals (APLS), Reata Pharmaceuticals (RETA), MorphoSys (MOR), Alkermes (ALKS), Corcept Therapeutics (CORT), Prelude Therapeutics (PRLD) and Agios Pharmaceuticals (AGIO).
View all of PTI's competitors.

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the following people:

Ms. Meenu Chhabra, Pres, CEO & Director (Age 48, Pay $844.78k)
Dr. Marija Zecevic, Chief Commercial Officer (Age 46, Pay $530.46k)
Michael L. Alfieri, Head of Fin.
Dr. Benito Munoz, Chief Scientific Officer (Age 58)
Ms. Janet L. Smart Esq., Ph.D., J.D., Sr. VP of Legal Affairs (Age 63)
Dr. Geoffrey S. Gilmartin, Chief Medical Officer (Age 52)
Ms. Claudia Styslinger, Investor Relations Exec.

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $21.43.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $1.12 billion and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is www.proteostasis.com.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here